March 4 - Moderna shares rose about 10% in premarket trading after the company reached a settlement that resolves a prolonged legal dispute over the lipid nanoparticle (LNP) technology that underpinned its COVID-19 vaccine.
Under the agreement, Moderna will make payments totaling up to $2.25 billion to a Genevant subsidiary owned by Roivant Sciences and to Arbutus Biopharma, ending U.S. and international legal actions that accused Moderna of unauthorized use of the LNP technology in its COVID vaccine.
The arrangement calls for Moderna to pay $950 million upfront in July 2026, with an additional $1.3 billion payable depending on the result of a separate legal appeal. The company will not owe royalties for use of the technology in future vaccines, a provision market watchers described as a significant benefit for Moderna.
Analysts said the settlement removes a cloud over the company and allows investors to refocus on Moderna's clinical pipeline, particularly its oncology programs.
"The company (now) has certainty it is well funded through multiple late-stage oncology readouts expected in 2026 that represent new long-term growth drivers," said William Blair analyst Myles Minter.
Citi analyst Geoffrey Meacham noted that the payments are lower than some Wall Street expectations, which had feared potential costs of more than $3 billion. Bernstein analyst Courtney Breen cautioned, however, that if the contingent $1.3 billion payment becomes necessary it could reduce Moderna's cash reserves to as little as $3.2 billion by 2026.
Moderna has projected its cash reserves for this year to be in the range of $4.5 billion to $5 billion. Breen said the settlement "narrows the tightrope" for the company, citing uncertainty around the timing and scale of Moderna's separate lawsuit against Pfizer and BioNTech over alleged infringement of mRNA patents, and noting management's historical tendency toward optimism.
Moderna previously sued Pfizer and BioNTech in 2022 alleging infringement of patents related to mRNA technology. In February, BioNTech filed a countersuit asserting that Moderna's next-generation COVID-19 shot, MNEXSPIKE, infringes one of its patents.
The resolution of the LNP litigation clears away a major legal overhang for Moderna, according to market participants, and shifts the narrative toward the company's development-stage oncology assets. At the same time, the contingent elements of the settlement mean material financial outcomes remain tied to other legal proceedings and potential future payments.
What this means for markets and sectors
- Biotechnology and pharmaceutical equities may see volatility as legal uncertainties are resolved and attention turns to product pipelines.
- Moderna's balance sheet and near-term cash flexibility will be watched closely by investors given the size and contingency of the payments.